Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunogen Inc (IMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,376,945
  • Shares Outstanding, K 149,020
  • Annual Sales, $ 115,450 K
  • Annual Income, $ -96,010 K
  • 36-Month Beta 1.95
  • Price/Sales 11.39
  • Price/Cash Flow N/A
  • Price/Book 13.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.30
  • Number of Estimates 8
  • High Estimate -0.26
  • Low Estimate -0.33
  • Prior Year -0.37
  • Growth Rate Est. (year over year) +18.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.70 +6.21%
on 09/17/18
10.37 -10.90%
on 09/04/18
+0.20 (+2.21%)
since 08/20/18
3-Month
8.38 +10.25%
on 08/09/18
12.31 -24.94%
on 06/25/18
-1.97 (-17.57%)
since 06/20/18
52-Week
4.80 +92.50%
on 11/03/17
13.41 -31.10%
on 03/26/18
+2.71 (+41.50%)
since 09/20/17

Most Recent Stories

More News
Investor Expectations to Drive Momentum within Ingevity, First Industrial Realty Trust, ImmunoGen, PriceSmart, Pacific Gas & Electric, and Procter & Gamble -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ingevity Corporation (NYSE:NGVT),...

NGVT : 104.38 (+3.24%)
PCG : 46.92 (+0.45%)
PG : 85.36 (+1.62%)
IMGN : 9.24 (+4.76%)
FR : 31.90 (+1.88%)
PSMT : 85.30 (+2.03%)
ImmunoGen Announces Webcast of Presentation at the Canaccord Genuity Growth Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the...

IMGN : 9.24 (+4.76%)
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates

ImmunoGen (IMGN) reports wider-than-expected loss in Q2. Lower license and milestone fees result in substantial decrease in year-over-year revenues.

MRK : 70.78 (+1.14%)
IMGN : 9.24 (+4.76%)
NVS : 85.97 (+1.26%)
SNY : 44.15 (+0.57%)
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates

ImmunoGen (IMGN) delivered earnings and revenue surprises of -3.45% and -34.37%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

IMGN : 9.24 (+4.76%)
ImmunoGen (IMGN) Q2 Loss Wider, Revenues Miss

ImmunoGen posted wider-than-expected loss in the second quarter of 2018. Moreover, revenues missed estimates, significantly decreasing year over year.

IMGN : 9.24 (+4.76%)
ImmunoGen Reports Recent Progress and Second Quarter 2018 Operating Results

--Encouraging Combination Data Reported from FORWARD II Expansion Cohort of Mirvetuximab with Avastin(R); Initial Data from Expansion Cohort in Combination with Keytruda(R) to be Presented at ESMO

IMGN : 9.24 (+4.76%)
ImmunoGen, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / July 27, 2018 / ImmunoGen, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on July 27, 2018 at 8:00 AM Eastern Time.

IMGN : 9.24 (+4.76%)
What's in Store for ImmunoGen (IMGN) This Earnings Season?

ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.

KERX : 3.14 (+6.08%)
HZNP : 18.84 (-0.05%)
IMGN : 9.24 (+4.76%)
RHHBY : 30.6000 (+0.16%)
First Week of September 21st Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the September 21st expiration.

IMGN : 9.24 (+4.76%)
ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference...

IMGN : 9.24 (+4.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade IMGN with:

Business Summary

ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended...

See More

Key Turning Points

2nd Resistance Point 9.60
1st Resistance Point 9.42
Last Price 9.24
1st Support Level 8.95
2nd Support Level 8.66

See More

52-Week High 13.41
Fibonacci 61.8% 10.12
Last Price 9.24
Fibonacci 50% 9.10
Fibonacci 38.2% 8.09
52-Week Low 4.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar